<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BE) and <z:mpath ids='MPATH_589'>dysplasia</z:mpath> are candidates for chemopreventive strategies to reduce <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk </plain></SENT>
<SENT sid="1" pm="."><plain>We determined the effects of difluoromethylornithine (DMFO) on mucosal <z:chebi fb="0" ids="51349">polyamines</z:chebi>, gene expression, and histopathology in BE </plain></SENT>
<SENT sid="2" pm="."><plain>Ten patients with BE and low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> participated in a single-arm study of DFMO (0.5 g/m(2)/d) given continuously for 6 months </plain></SENT>
<SENT sid="3" pm="."><plain>Esophagoscopy with biopsies was conducted at baseline, 3, 6, and 12 months </plain></SENT>
<SENT sid="4" pm="."><plain><z:mpath ids='MPATH_589'>Dysplasia</z:mpath> was graded by a gastrointestinal pathologist </plain></SENT>
<SENT sid="5" pm="."><plain>Audiology was assessed (at baseline and at 6 months) </plain></SENT>
<SENT sid="6" pm="."><plain>Mucosal <z:chebi fb="0" ids="51349">polyamines</z:chebi> were measured by high-performance liquid chromatography </plain></SENT>
<SENT sid="7" pm="."><plain>Microarray-based gene expression was analyzed using a cDNA two-color chip </plain></SENT>
<SENT sid="8" pm="."><plain>DFMO suppressed levels of the <z:chebi fb="0" ids="51349">polyamines</z:chebi> <z:chebi fb="0" ids="17148">putrescine</z:chebi> (P = 0.02) and <z:chebi fb="0" ids="16610">spermidine</z:chebi> (P = 0.02) and the <z:chebi fb="0" ids="16610">spermidine</z:chebi>/<z:chebi fb="0" ids="15746">spermine</z:chebi> ratio (P &lt; 0.01) in dysplastic BE (6 months vs. baseline) that persisted at 6 months following drug cessation </plain></SENT>
<SENT sid="9" pm="."><plain>Among the top 25 modulated genes, we found those regulating p53-mediated cell signaling (RPL11), cell-cycle regulation (cyclin E2), and cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> and invasion (Plexin1) </plain></SENT>
<SENT sid="10" pm="."><plain>DFMO downregulated Kr√ºppel-like factor 5 (KLF5), a transcription factor promoting cell proliferation, and suppressed RFC5 whose protein interacts with proliferating cell nuclear antigen </plain></SENT>
<SENT sid="11" pm="."><plain>Histopathology showed regression of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (n = 1), stable disease (n = 8), and progression to high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (n = 1) </plain></SENT>
<SENT sid="12" pm="."><plain><z:chebi fb="0" ids="51349">Polyamines</z:chebi> were suppressed in the responder to a greater extent than in stable cases </plain></SENT>
<SENT sid="13" pm="."><plain>DFMO was well tolerated, and one patient had subclinical, unilateral <z:e sem="disease" ids="C0235280" disease_type="Disease or Syndrome" abbrv="">ototoxicity</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>DFMO suppressed mucosal <z:chebi fb="0" ids="51349">polyamines</z:chebi> and modulated genes that may be mechanistically related to its chemopreventive effect </plain></SENT>
<SENT sid="15" pm="."><plain>Further study of DFMO for the chemoprevention of <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> in BE patients is warranted </plain></SENT>
</text></document>